Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

GSK And Valeant Partner On Epilepsy Candidates

28 Aug 2008

$125 million upfront deal could ameliorate impact of 2010 Lamictal patent expiry for GSK.

Related Content

GSK’s Lamictal Extended Release Is “Approvable” At FDA

24 Sep 2007

Valeant Will Trim Its Focus To North America, Concentrate On Neurology And Dermatology

27 Mar 2008

Valeant Estimates Peak Sales Of $1.5 Billion For Epilepsy Drug

14 May 2008

Valeant Seeking Return To Growth With New Chief Executive

04 Feb 2008

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2024 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.